← Search

Table · dataset · 2026

Supplemental Material for:Comprehensive quality of life assessment in advanced renal cell carcinoma: Final results of the PRO Kidney study

Listed in figshare and Loughborough Research Repository — shown once because both records carry DOI 10.6084/m9.figshare.33963202.v1

Description

<p dir="ltr"><b>Introduction: </b>Patient-reported outcomes (PROs), particularly health-related quality of life (HRQoL) and treatment-related side effects, are crucial for guiding treatment in advanced renal cell carcinoma (aRCC). <a href="" target="_blank">We report longitudinal PRO data prospectively collected in a real-world aRCC setting during the targeted therapy era.</a></p><p dir="ltr"><b>Methods: </b>Patients with aRCC were enrolled in the prospective, observational, multicenter PRO Kidney cohort study (NCT02537743) from 2015-2018.

PROs were assessed tablet-based from baseline up to 24 months using validated instruments (NCCN‑FACT FKSI‑19, FACIT‑Fatigue), and custom questions on RCC-/treatment-specific symptoms (IOAE) and daily life impact (IODAYA). Descriptive statistics were used, except for time-to-deterioration (TTD) analysis.</p><p dir="ltr"><b>Results:</b> Of 98 patients signing informed consent, 90 with at least one completed PRO questionnaire were included in the full analysis set; 80 with baseline questionnaires were analyzed for HRQoL.

Read the rest (2 more)

Median age was 68 years; 78.9% (n=71) presented with clear-cell histology and 44.4% (n=40) were at intermediate MSKCC risk. The most frequently used first-line treatments were pazopanib (56.7%; n=51) and sunitinib (23.3%; n=21). Clinically relevant deterioration in HRQoL was observed in 52.5% (n=42) of patients within six months (median TTD 5.1 months, 95%CI 2.9-7.0).

Treatment was associated with fatigue, nausea, diarrhea and altered taste, independent of treatment regimen. Most patients reported being content with their HRQoL and were able to continue with their day-to-day activities.</p><p dir="ltr"><b>Conclusion:</b> Despite treatment-related side effects and HRQoL deterioration in some patients, most maintained daily functioning and reported acceptable overall HRQoL, suggesting that tyrosine kinase inhibitor monotherapy may remain a valuable option, particularly for those with contraindications to immunotherapy.</p>

Links

Where it is published

Catalogue records · 1

Topics

Inferred from text
Longitudinal study 65% · Oncology and carcinogenesis 69%
Provenance · 2 source records, 30 field assertions
SourceKeyLast seenRaw
figshareoai:figshare.com:article/3396320211 d agoJSON v1
Loughborough Research Repositoryoai:figshare.com:article/3396320211 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · figshare comconnector:figshare_com@1.0.0
concepts[field].anzsrc:group:3211enrichment · figshare comtaxonomy-embedding@1.0.0title+keywords+description (69%)
concepts[field].local:field:astronomymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:chemistrymapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:chemistrymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:computer-science-aimapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:computer-science-aimapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:economics-financemapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:economics-financemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:engineeringmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:engineeringmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:humanitiesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:humanitiesmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:materials-sciencemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:mathematics-statisticsmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:ocean-atmosphericmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:psychology-behavioralmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:social-sciencemapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:social-sciencemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[method].local:method:longitudinal-studyenrichment · figshare comkeyword-concept-rules@1.0.0title+description (65%)
descriptionsource · figshare comconnector:figshare_com@1.0.0/metadata/dc/description
licensesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/rights
publication_datesource · figshare comconnector:figshare_com@1.0.0
titlesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/title